Amvuttra (Vutrisiran)

Amvuttra (vutrisiran) is a transthyretin-directed small interfering RNA widely used for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults.

Recommended Dosage: The recommended dosage of Amvuttra is 25 mg administered by subcutaneous (SC) injection once every 3 months. 

In case a dose is missed, administer as quickly as possible. Resume dosing with Amvuttra every 3 months from the most recently administered dose.

• By scaling down serum transthyretin (TTR) protein, Amvuttra 25 mg/0.5 mL treatment leads to a reduction in serum vitamin A (retinol) levels. Serum vitamin A levels under the lower limit of normal must be corrected and any ocular signs or symptoms due to vitamin A deficiency need to be assessed before initiating therapy with Amvuttra.
  
• Patients taking Amvuttra treatment should take oral supplementation of around, but not more than, 2 500 IU to 3 000 IU vitamin A daily to scale down the probable risk of ocular symptoms because of vitamin A deficiency. Ophthalmological evaluation is needed in case patients develop ocular symptoms suggestive of vitamin A deficiency, including night blindness, reduced vision, eye inflammation, persistent dry eyes, corneal inflammation or ulceration, corneal thickening, or corneal perforation.
  
• Treatment with Amvuttra injection decreases serum levels of vitamin A. Both extremely high or extremely low vitamin A levels may be related to an increased probability of fetal malformation. Therefore, pregnancy needs to be excluded prior to initiating this treatment, and women of childbearing age should consider appropriate contraception.
  
• Due to the potential teratogenic probability arising from unbalanced vitamin A levels, Amvuttra therapy should be avoided during pregnancy. As a precautionary concern, vitamin A and thyroid stimulating hormone levels need to be obtained early in pregnancy. Appropriate monitoring of the fetus should be carried out, mainly during the first trimester.
  

What documents are required to import AMVUTTRA to India?

AMVUTTRA (vutrisiran) injection can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

AMVUTTRA (vutrisiran injection) is a (prescription medicine, prescription medication, or prescription drug) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Amvuttra in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of AMVUTTRA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Amvuttra 25 mg/0.5 mL price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the AMVUTTRA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Amvuttra®?

Vutrisiran is a Generic Name for the trade name drug Amvuttra®.

What is the Manufacturer’s Name of Amvuttra®?

Amvuttra® is manufactured by Alnylam Pharmaceuticals, Inc.

Is Amvuttra® approved by the FDA?

Yes, Amvuttra® is approved by the FDA. Date of first approval: June 13, 2022.

Where can I get Amvuttra® at the best price in India?

To get the best Amvuttra price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Amvuttra®, a valid medical prescription is required from a treating physician.

What is the dosage and form of Amvuttra® supplied?

Amvuttra® is supplied as Injections: 25 mg/0.5 mL in a single-dose prefilled syringe for subcutaneous administration. 

What are the most common side effects of Amvuttra®? 

The most common side effects of Amvuttra® are dyspnea, arthralgia, and decreased vitamin A. 

How much does Amvuttra® cost in India?

The cost of Amvuttra in India can vary. In order to procure this medicine legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Amvuttra®?

Store at 2-30°C (36-86°F) in the original carton, until ready for use. It is not advisable to freeze this drug.

Is it safe to buy Amvuttra® online in India?

Yes, one can buy Amvuttra online in India at the lowest price from the Indian Pharma Network (IPN) if it is not (yet) registered or available in their country. We can help facilitate the legal supply of Amvuttra® through legal channels.